Ratios
10-year key figure history for Curasight turnover, profit, dividend, equity, PE and PB.
Stockprice
Price movement for Curasight with index and moving average MA50 and MA200.
Description
Curasight is a Phase II clinical company based in Copenhagen, Denmark. The company is a pioneer in the field of using the Positron Emissions Tomography (PET) imaging platform targeted at the receptor uPAR, which is a known biomarker for cancer aggressiveness, which will be used for improved diagnosis in several types of cancer. PET imaging, usually combined with CT as PET / CT, is used to create images where the biology of the disease can be studied. The principle is that a radiolabeled tracer is injected and bound to the tissues, e.g. to a tumor, after which the radioactivity can be placed using a PET scanner.